Status:
COMPLETED
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Lead Sponsor:
GlaxoSmithKline
Conditions:
Lymphoma, Large-Cell, Diffuse
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with DLBCL
- and relapse after complete remission or disease progression after partial remission who are ineligible for autologous stem cell transplantation
- and relapse after complete remission or disease progression after partial remission following autologous stem cell transplantation.
Exclusion
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00622388
Start Date
December 1 2007
End Date
August 1 2014
Last Update
July 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
London, London, United Kingdom, EC1M 6BQ